Navigation Links
Dendreon Announces Increased Capacity and Significant Reimbursement Decisions Supporting Broad Availability of PROVENGE
Date:6/30/2011

ions were reported in patients in the PROVENGE group.

To fulfill a post marketing requirement and as a part of the company's ongoing commitment to patients, Dendreon will conduct a registry of approximately 1,500 patients to further evaluate a small potential safety signal of cerebrovascular events. In four randomized clinical trials of PROVENGE in prostate cancer patients, cerebrovascular events were observed in 3.5% of patients in the PROVENGE group compared with 2.6% of patients in the control group.

For more information on PROVENGE, please see the full Prescribing Information at www.provenge.com or call 1-877-336-3736.

About Prostate Cancer

According to the American Cancer Society, prostate cancer is the most common non-skin cancer in men in the United States and the third most common cancer worldwide. More than two million men in the United States have prostate cancer, with an estimated 240,890 new cases and approximately 33,720 men expected to die from the disease in 2011.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first product, PROVENGE® (sipuleucel-T), was approved by the U.S. Food and Drug Administration (FDA) in April 2010 for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington and is t
'/>"/>

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
2. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
3. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
4. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
5. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
6. Dendreon Reports Third Quarter 2008 Financial Results
7. Dendreon Announces Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference
8. Dendreon Announces Webcast Presentation at Eleventh Annual BIO CEO & Investor Conference
9. Dendreon Reports Fourth Quarter and 2008 Year End Financial Results
10. Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer
11. Dendreon Announces Data Presentations and Webcast at AUA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... FORT LAUDERDALE, Fla. , Sept. 17, 2014 ... signed an agreement to form a Special Purpose Vehicle in ... based Jatropha centric agro energy company. The SPV shall ... U.S. registered entity with AFAI as majority shareholder. The SPV ... Africa , particularly Ethiopia . ...
(Date:9/17/2014)... RXi Pharmaceuticals Corporation (NASDAQ: ... developing and commercializing innovative therapies addressing major unmet ... has been granted a patent by the United ... delivery system for delivering its "original" RNAi compounds ... treatment of diseases with an inflammatory component. Potential ...
(Date:9/17/2014)... CA (PRWEB) September 17, 2014 Escape Alert, ... for pets which will alert owners if their pet has ... GPS from an implanted microchip in the pet’s body. This ... microchips for pets have been around for many years, they ... are not able to track a pet’s location or alert the ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 The ... committed to lowering the barriers to innovation in ... the appointment of Carmen Nitsche as Executive Director ... to expand its global reach. , Carmen joins ... Vice President, Corporate Development. At Accelrys, she managed ...
Breaking Biology Technology:AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 2AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 2RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 4Implantable Microchip for Pets with GPS Tracking - Patent Filed by Escape Alert, LLC. 2Implantable Microchip for Pets with GPS Tracking - Patent Filed by Escape Alert, LLC. 3Pistoia Alliance Expands Business Development with Appointment of Carmen Nitsche 2
... photonics and renewable energy will be the focus of ... to 14, 2009 at McMaster University in Hamilton, Ontario, ... in conjunction with the event. , The 4th Nano ... the 14th Canadian Semiconductor Technology Conference (CSTC2009) will bring ...
... UC Riverside have made an accidental discovery in ... information in computers can be transported or stored. ... electrons possess that makes them behave like tiny ... of spin-based semiconductor technology such as ultrahigh-speed computers. ...
... programs give sponsors easy-to-use tools to store, mine and ... transfer knowledge base to ensure enrollment success, NEWTON, ... technology leader, announced the release of a new,product, "Center ... in-house recruitment capabilities for clinical,trial sponsors. The goal is ...
Cached Biology Technology:Joint nanotechnology forum to focus on electronics, photonics, renewable energy 2Discovery by UC Riverside physicists could enable development of faster computers 2Discovery by UC Riverside physicists could enable development of faster computers 3TCN e-Systems Offers Trial Sponsors Solutions for Creating In-House Center of Excellence in Patient Recruitment 2TCN e-Systems Offers Trial Sponsors Solutions for Creating In-House Center of Excellence in Patient Recruitment 3TCN e-Systems Offers Trial Sponsors Solutions for Creating In-House Center of Excellence in Patient Recruitment 4
(Date:9/17/2014)... learned a great deal about complex social behavior by ... something to teach too. , With their unusually large ... parrots live in a complex social environment---not merely in ... or ants, but in a dynamic setting of alliances ... intelligent mammals: dolphins, whales, primates, and social carnivores, like ...
(Date:9/16/2014)... Environmental Health at the Mailman School of Public Health ... asthma and prenatal exposure to two phthalates used in ... in the journal Environmental Health Perspectives . ... higher levels of the chemicals, butylbenzyl phthalate (BBzP) and ... percent increase in risk of developing asthma between age ...
(Date:9/16/2014)... CLEVELAND, Ohio (September 17, 2014)The North American Menopause ... for the comprehensive care of midlife womenon everything ... feature, "The North American Menopause Society Recommendations for ... today in the Society,s journal Menopause . ... recommendations for the care of midlife women freely ...
Breaking Biology News(10 mins):Being social: Learning from the behavior of birds 2Phthalates heighten risk for childhood asthma 2Phthalates heighten risk for childhood asthma 3
... A team of scientists from the University Hospitals of ... bowel diseases have low bone mass and poor bone architecture ... at increased risk of fracture. Inflammatory bowel disease ... inflammation of the bowel. Two of the most common disorders ...
... new study presented today at the World Congress on ... a commonly used injectible contraceptive, is associated with higher ... in combination with estrogens. Depot medroxyprogesterone acetate ... birth control drug which is injected every 3 months. ...
... muscle tissue experiences trauma or disease, such as ... as "satellite cells" respond to repair and regenerate ... neuromuscular diseases, such as muscular dystrophy, which affect ... researchers have used time-lapse photography to document satellite ...
Cached Biology News:Caught on tape: Muscle stem cells captured on video by MU researcher 2
Anti-ADAM-12 (Meltrin Alpha); amino terminal region; rabbit host...
Mouse monoclonal [3G8] to MDMA ( Abpromise for all tested applications)....
Fluorescein isothiocyanate (FITC) mouse anti-human IFN-alpha2 25 tests...
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
Biology Products: